Percorrer por autor "Charpentier, Charlotte"
A mostrar 1 - 3 de 3
Resultados por página
Opções de ordenação
- HIV-2 EU—supporting standardized HIV-2 drug resistance interpretation : an updatePublication . Charpentier, Charlotte; Berzow, Dirk; Hingrat, Quentin Le; Kaiser, Rolf; Gomes, Perpétua; Miranda, Ana Cláudia; Damond, Florence; Ghosn, Jade; Kampen, Jeroen J. A. van; Jensen, Björn-Erik Ole; Böhm, Michael; Wensing, Annemarie M. J.; Descamps, Diane; Obermeier, MartinHuman immunodeficiency virus type 2 (HIV-2) is an attenuated retroviral infection characterized by specific natural susceptibility to antiretroviral drugs and acquired resistance profiles. Based on the latest knowledge of phenotypic data and clinical follow-up, HIV-2 resistance interpretation rules have been updated and implemented in a freely available resistance analysis tool.
- Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International CollaborationPublication . Rhee, Soo-Yon; Varghese, Vici; Holmes, Susan P.; Van Zyl, Gert U.; Steegen, Kim; Boyd, Mark A.; Cooper, David A.; Nsanzimana, Sabin; Saravanan, Shanmugam; Charpentier, Charlotte; Oliveira, Tulio de; Etiebet, Mary-Ann A.; Garcia, Federico; Goedhals, Dominique; Gomes, Perpétua; Günthard, Huldrych F.; Hamers, Raph L.; Hoffmann, Christopher J.; Hunt, Gillian; Jiamsakul, Awachana; Kaleebu, Pontiano; Kanki, Phyllis; Kantor, Rami; Kerschberger, Bernhard; Marconi, Vincent C.; Ndahimana, Jean D'amour; Ndembi, Nicaise; Ngo-Giang-Huong, Nicole; Rokx, Casper; Santoro, Maria M.; Schapiro, Jonathan M.; Schmidt, Daniel; Seu, Lillian; Sigaloff, Kim C. E.; Sirivichayakul, Sunee; Skhosan, Lindiwe; Sunpath, Henry; Tang, Michele; Yang, Chunfu; Carmona, Sergio; Gupta, Ravindra K.; Shafer, Robert W.
- Optimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care : evidence, implementation, and unanswered questionsPublication . Geretti, Anna Maria; Boffito, Marta; Bonora, Stefano; Braun, Patrick; Charpentier, Charlotte; Garcia, Federico; Ghosn, Jade; Gomes, Perpétua; Marcelin, Anne-Geneviève; Mesplède, Thibault; Parczewski, Milosz; Ring, Kyle; Santoro, Maria Mercedes; Solas, Caroline; Wolf, Eva; Orkin, ChloeCabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.